Mavacamten HCM denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for mavacamten hcm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Mavacamten as Experimental — and Why That Denial Is Incorrect and Appealable

Mavacamten is FDA-approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults. An "experimental" or "investigational" denial for an FDA-approved drug is almost always the result of a lag between FDA action and the insurer's internal clinical policy update, an incorrect drug coding, or a blanket policy that has not been reviewed against current regulatory status. Regardless of the reason, an experimental denial for an FDA-approved drug is legally and clinically untenable and is one of the strongest denial types to challenge on appeal.

## Why This Denial Is Appealable

Federal and state law, as well as most plan documents, define "experimental" by reference to FDA approval status and accepted medical practice. Mavacamten has received full FDA approval for its labeled indication. Applicable cardiology professional society guidelines also recognize mavacamten in the management of symptomatic oHCM. An insurer that applies an experimental label to a drug with full FDA approval for the patient's exact indication has a very high bar to defend that classification at external review.

## Federal Appeal Framework

• Internal appeal: File promptly within the window in your denial letter. Attach documentation of FDA approval status and the relevant sections of Aetna's own clinical policy to highlight the inconsistency.
• External review (ACA §2719): After exhausting internal appeals, request independent external review — this is available within approximately four months of the final internal denial for most non-grandfathered plans. External reviewers are independent of the insurer and frequently overturn experimental denials for FDA-approved drugs.
• ERISA §503: Employer-plan members have full-and-fair review rights.
• Expedited review: Available when delay would seriously jeopardize health.

## Documentation to Gather

• FDA approval documentation: Print the FDA drug approval page and prescribing label confirming approved indication for symptomatic oHCM.
• Diagnosis confirmation: Specialist records establishing the diagnosis that matches the FDA-approved indication.
• Prescriber medical-necessity letter: A letter from the treating cardiologist confirming that the prescription is for the FDA-approved indication, referencing current professional society guidelines.
• Applicable guidelines: Cite the relevant cardiology society guideline documents (without quoting specific numbers) that support mavacamten for this indication.
• Aetna policy review: Request Aetna's current clinical policy in writing and note whether it has been updated to reflect FDA approval.

## Criteria-Mapping Structure

| Denial Basis | Rebuttal Documentation | |---|---| | Drug classified as experimental | FDA approval letter / prescribing label (confirm indication matches) | | Not accepted medical practice | Applicable cardiology society guideline reference | | Indication not covered | Diagnosis records matching FDA-approved indication exactly |

External reviewers overturning these denials at high rates for FDA-approved drugs — if the internal appeal is denied, pursue external review without delay.